Insilico's Rentosertib Reverses Biological Age Across Six Clocks. The Protein Signatures Agree. That Is The Point.

Insilico Medicine published a study in Nature Biotechnology showing that their AI-discovered IPF candidate rentosertib reduced predicted biological age across all six proteomic aging clocks tested. The international collaboration included scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University, and Westlake University. Insilico's 2026 contract transactions reached approximately $7.3 billion, with cumulative major collaborations since 2021 totaling roughly $11 billion.

This demonstrates the principle of convergent validation. When six independent proteomic models, each built on different protein signatures, all point in the same direction, you have something considerably more robust than a single biomarker could ever provide. The mental model here is simple. One clock is a guess. Six clocks agreeing is a finding.

Insilico Medicine, a clinical-stage generative AI drug discovery company, conducted the study with an international team spanning six major research institutions. Their AI-driven R&D pipeline produced rentosertib, which is now showing potential for biological age reversal in addition to its primary idiopathic pulmonary fibrosis application.